Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: TNF-RI (serum)

Search for Biomarkers

Analyte:

TNF-RI (serum)

Platform:

Matrix:

Human Serum

Status:

Experienced Running

Sensitivity-LLOQ/ULOQ:

LLOQ: 244 pg/mL
ULOQ: 250,000 pg/mL

Biological or Clinical Significance:

Tumor necrosis factor receptor 1 (TNFR1), also known as tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), is a ubiquitous membrane receptor that binds tumor necrosis factor-alpha (TNFα).

Germline mutations of the extracellular domains of this receptor were found to be associated with the human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS) or periodic fever syndrome.[5] Impaired receptor clearance is thought to be a mechanism of the disease. Mutations in the TNFRSF1A gene is associated with elevated risk of multiple sclerosis. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are associated with more severe psychotic symptoms. High serum levels is also associated with cognitive impairment and dementia.

References:

Speak to a Scientist

















What would you like to discuss?

With whom will we be speaking?






I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.


biomarker services

Services

See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

Explore our services

case studies

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Read our case studies